SLS - Latest News
SELLAS Life Sciences Group, Inc. (SLS), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $930.1M. Beta to the broader market is 2.24.
The article list below shows the most recent SLS headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent SLS Headlines
SELLAS Life Sciences to Participate in Upcoming Investor Conferences
globenewswire.com - May 14, 2026
NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharm
SELLAS Life Sciences Nears Pivotal Trial Readout As Leukemia Pipeline Progresses
benzinga.com - May 13, 2026
SELLAS Life Sciences Group Inc. (NASDAQ:SLS) reported first-quarter (Q1) 2026 financial results on Tuesday while highlighting progress across its acu
SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com - May 12, 2026
– Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company that
Sellas Life Sciences: 'Hold' As Phase 3 AML Study Progresses To Key Event
seekingalpha.com - Apr 23, 2026
SELLAS Life Sciences is rated 'Hold' due to pending phase 3 REGAL data for GPS in AML after CR2, a major 2026 catalyst. The company's GPS targets WT1
Wall Street Analysts Think SELLAS Life Sciences Group, Inc. (SLS) Could Surge 66.09%: Read This Before Placing a Bet
zacks.com - Apr 20, 2026
The mean of analysts' price targets for SELLAS Life Sciences Group, Inc. (SLS) points to a 66.
How News Affects SLS Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track SLS's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked SLS news questions
- What is the latest SLS news headline?
- The most recent SLS headline (May 14, 2026) is "SELLAS Life Sciences to Participate in Upcoming Investor Conferences". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the SLS news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What SLS news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual SLS options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.